[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452168":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":56,"collaborators":59,"id":62,"slug":20,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":20,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Anlotinib and Penpulimab arm","EXPERIMENTAL","Pre-operative IMRT with concurrent and sequential Anlotinib and Penpulimab",[13],"Drug: Anlotinib hydrochloride",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Anlotinib hydrochloride","Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ning-Ning Lu","CONTACT","+868611804268","Ning-Ning.Lu@hotmail.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42,45,49,52,54],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":26},"Ningning Lu, Doctor","+86 01087787630",{"name":46,"role":24,"phone":47,"phoneExt":20,"email":48},"Shu-Lian Wang, M.D.","+86 01087788280","wsl20040118@yahoo.com",{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"Shu-Lian Wang, M.D","PRINCIPAL_INVESTIGATOR",{"name":53,"role":51,"phone":20,"phoneExt":20,"email":20},"Sheng-Ji Yu, M.D",{"name":55,"role":51,"phone":20,"phoneExt":20,"email":20},"Ning-Ning Lu, M.D.",{"type":51,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"NINGNING LU","Principle Investigator",[60],{"name":61,"class":6},"Beijing Jishuitan Hospital","100452168",false,"NCT05167994","Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）","Preoperative Intensity-Modulated Radiotherapy (IMRT) Combined With Concurrent Anlotinib Hydrochloride and Penpulimab for Localized Extremity or Trunk Sarcoma","SPARE-01","Inclusion Criteria:\n\n* Age older than 18-yo\n* Histology proven soft tissue sarcoma of truncal or extremity, deemed appropriate for preoperative radiotherapy and conservative surgery by multidisciplinary discussion.\n* ECOG 0-3\n* Histology reviewed by reference pathologist\n* Lesion can be assessed\n* Can tolerate radiotherapy and Anlotinib\n* Agree contraception.\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* No gross tumor post-resection in other center.\n* Contraindications to Anlotinib, including allergic to Anlotinb, active bleeding, ulcer, enteric perforation, enteric obstruction, uncontrolled hypertension, Grade 3 to 4 cardiac insufficiency (per NYHA criteria), and severe hepatic or renal insufficiency (Grade 4), etc.\n* Dermatofibrosarcoma protuberans(DFSP), Desmoids, etc.\n* Benign histology\n* Secondary cancer within 5 years (except cervical carcinoma in situ or early-stage skin basal cell carcinoma)\n* STS can be cured by extensive operation alone.\n* Previous irradiation to the same area\n* Radiological evidence of distant metastases\n* Other contraindications, can't tolerate operation or other treatment needed in this study.\n* Neoadjuvant chemotherapy given or planned.","ALL","18 Years",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride and Penpulimab for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.",[79,80,81,82,83,84],"Sarcoma,Soft Tissue","Extremity","Trunk","Anlotinib","Intensity-modulated Radiotherapy","Major Wound Complications","2026-06-03",{"date":87,"type":88},"2026-06-04","ACTUAL",{"date":90,"type":88},"2020-05-01",{"date":92,"type":73},"2027-12-31",{"name":5,"class":6},1]